Skip to main content

2021

Persbericht

Pharming publiceert resultaten van klinische studies naar de behandeling van COVID-19 met RUCONEST®

Pharming Group NV (“Pharming” of “de Onderneming”) (Euronext Amsterdam: PHARM/NASDAQ: PHAR) maakt de topline resultaten bekend van twee gerandomiseerde, open label, gecontroleerde, klinische pilot-onderzoeken met patiënten die in het ziekenhuis waren opgenomen met COVID-19 en die werden behandeld met RUCONEST® voor de preventie van een ernstige SARS-CoV-2-infectie. Het primaire eindpunt in beide onderzoeken was ‘de ernst van de ziekte op dag 7 van de 7-punts WHO-schaal’.

Read more
Press release

Pharming announces results from clinical trials for the treatment of COVID-19 with RUCONEST®

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/NASDAQ: PHAR) announces the topline results from two randomized, open label, controlled, pilot clinical trials of patients hospitalized with COVID-19 treated with RUCONEST® (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infection. The primary endpoint in both studies was disease severity on the 7-point WHO ordinal scale on Day 7.

Read more

2020

Press release

Pharming announces enrolment of first patient in US clinical trial for the treatment of COVID-19 with RUCONEST®

Pharming Group N.V. announces that the first patient has been enrolled in a randomised, open label, parallel group, controlled, pilot clinical trial in up to 120 patients hospitalised with confirmed COVID-19 treated with RUCONEST® (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infections at the Valley Hospital in Ridgewood, New Jersey in the United States.

Read more
Press release

Pharming announces the publication of data from a compassionate use programme of RUCONEST® in COVID-19 patients in a peer-reviewed journal

Pharming Group N.V. today announces the publication of data in the peer-reviewed journal, Frontiers in Immunology, from a compassionate use programme of five patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalised with related severe pneumonia that were treated with RUCONEST® (recombinant human C1 inhibitor, conestat alfa) at the University Hospital Basel, Switzerland.

Read more
Press release

Pharming announces enrolment of first patient in multinational clinical trial for the treatment of COVID-19 with RUCONEST®

Pharming Group N.V. announces that the first patient has been enrolled in a randomized, controlled, investigator-initiated clinical trial in up to 150 patients for the treatment with RUCONEST® (recombinant human C1 inhibitor) of patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalised with related severe pneumonia at the University Hospital Basel in Basel, Switzerland.

Read more

Filter

Cookies: This website uses cookies Check the cookies page for more information Accept Decline